R&D valuation model audit and upgrade

One of the 10 largest pharmaceutical companies in the world had internally developed a comprehensive R&D valuation (template) model that was used to evaluate all (100+) pipeline drugs. The results of the model were used to support go-no-go decisions, R&D portfolio prioritizations and to support M&A transactions. However, the model had never been independently audited, didn’t have comprehensive documentation and training materials, and users had requested a variety of enhancements. EpiX completed a thorough audit of the model and made a number of critical enhancements that greatly increased the model’s speed and accuracy.

Learn more about this project    Back to all case studies